

# Francisco Abad-Santos

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5515781/publications.pdf>

Version: 2024-02-01

160  
papers

3,556  
citations

196777

29  
h-index

232693

48  
g-index

178  
all docs

178  
docs citations

178  
times ranked

5642  
citing authors

#	ARTICLE	IF	CITATIONS
1	Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fluoropyrimidines. <i>Clinical and Translational Oncology</i> , 2022, 24, 483-494.	1.2	19
2	A Case-Control of Patients with COVID-19 to Explore the Association of Previous Hospitalisation Use of Medication on the Mortality of COVID-19 Disease: A Propensity Score Matching Analysis. <i>Pharmaceuticals</i> , 2022, 15, 78.	1.7	8
3	Patients'™ Perceptions of Pharmacogenetic Testing and Access to Their Results: State of the Art in Spain and Systematic Review. <i>Journal of Personalized Medicine</i> , 2022, 12, 270.	1.1	3
4	Genotype-Guided Prescription of Azathioprine Reduces the Incidence of Adverse Drug Reactions in TPMT Intermediate Metabolizers to a Similar Incidence as Normal Metabolizers. <i>Advances in Therapy</i> , 2022, 39, 1743-1753.	1.3	10
5	Subcutaneous IL-6 Inhibitor Sarilumab vs. Standard Care in Hospitalized Patients With Moderate-To-Severe COVID-19: An Open Label Randomized Clinical Trial. <i>Frontiers in Medicine</i> , 2022, 9, 819621.	1.2	4
6	Role of Pharmacogenetics in the Treatment of Acute Myeloid Leukemia: Systematic Review and Future Perspectives. <i>Pharmaceutics</i> , 2022, 14, 559.	2.0	6
7	First-in-human phase I clinical trial of a TLR4-binding DNA aptamer, ApTOLL: Safety and pharmacokinetics in healthy volunteers. <i>Molecular Therapy - Nucleic Acids</i> , 2022, 28, 124-135.	2.3	25
8	The second-generation antipsychotic drug aripiprazole modulates the serotonergic system in pancreatic islets and induces beta cell dysfunction in female mice. <i>Diabetologia</i> , 2022, 65, 490-505.	2.9	9
9	Pharmacogenetics of Donepezil and Memantine in Healthy Subjects. <i>Journal of Personalized Medicine</i> , 2022, 12, 788.	1.1	3
10	Transmembrane protease serine 2 ( <i>TMPRSS2</i> ) rs75603675, comorbidity, and sex are the primary predictors of COVID-19 severity. <i>Life Science Alliance</i> , 2022, 5, e202201396.	1.3	3
11	Correction: Transmembrane protease serine 2 ( <i>TMPRSS2</i> ) rs75603675, comorbidity and sex are the primary predictors of Covid-19 severity. <i>Life Science Alliance</i> , 2022, 5, e202201545.	1.3	0
12	Population pharmacokinetic modelling of imatinib in healthy subjects receiving a single dose of 400Âmg. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 90, 125-136.	1.1	2
13	Safety and cardiovascular effects of multipleâ€dose administration of aripiprazole and olanzapine in a randomised clinical trial. <i>Human Psychopharmacology</i> , 2021, 36, 1-12.	0.7	10
14	Investigaci3n durante la pandemia por SARS-CoV-2. <i>Medicina ClÃnica</i> , 2021, 156, 39-40.	0.3	1
15	Combination of Tocilizumab and Steroids to Improve Mortality in Patients with Severe COVID-19 Infection: A Spanish, Multicenter, Cohort Study. <i>Infectious Diseases and Therapy</i> , 2021, 10, 347-362.	1.8	40
16	Metabolic Effects of Aripiprazole and Olanzapine Multiple-Dose Treatment in a Randomised Crossover Clinical Trial in Healthy Volunteers: Association with Pharmacogenetics. <i>Advances in Therapy</i> , 2021, 38, 1035-1054.	1.3	17
17	Impact of polymorphisms in transporter and metabolizing enzyme genes on olanzapine pharmacokinetics and safety in healthy volunteers. <i>Biomedicine and Pharmacotherapy</i> , 2021, 133, 111087.	2.5	12
18	Methylation in psoriasis. Does sex matter?. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e161-e163.	1.3	5

#	ARTICLE	IF	CITATIONS
19	Evaluation of Voriconazole CYP2C19 Phenotype-Guided Dose Adjustments by Physiologically Based Pharmacokinetic Modeling. <i>Clinical Pharmacokinetics</i> , 2021, 60, 261-270.	1.6	12
20	SLCO1B1 Phenotype and CYP3A5 Polymorphism Significantly Affect Atorvastatin Bioavailability. <i>Journal of Personalized Medicine</i> , 2021, 11, 204.	1.1	19
21	Epigenetics in Non-tumor Immune-Mediated Skin Diseases. <i>Molecular Diagnosis and Therapy</i> , 2021, 25, 137-161.	1.6	3
22	High-Fat Breakfast Increases Bioavailability of Albendazole Compared to Low-Fat Breakfast: Single-Dose Study in Healthy Subjects. <i>Frontiers in Pharmacology</i> , 2021, 12, 664465.	1.6	11
23	Dexketoprofen Pharmacokinetics is not Significantly Altered by Genetic Polymorphism. <i>Frontiers in Pharmacology</i> , 2021, 12, 660639.	1.6	1
24	Influence of Genetic Polymorphisms on the Response to Tramadol, Ibuprofen, and the Combination in Patients With Moderate to Severe Pain After Dental Surgery. <i>Clinical Therapeutics</i> , 2021, 43, e86-e102.	1.1	4
25	Acenocoumarol Pharmacogenetic Dosing Algorithm versus Usual Care in Patients with Venous Thromboembolism: A Randomised Clinical Trial. <i>Journal of Clinical Medicine</i> , 2021, 10, 2949.	1.0	4
26	Influence of CYP2D6 Phenotypes on the Pharmacokinetics of Aripiprazole and Dehydro-Aripiprazole Using a Physiologically Based Pharmacokinetic Approach. <i>Clinical Pharmacokinetics</i> , 2021, 60, 1569-1582.	1.6	11
27	Pharmacokinetics and Safety of a Bilastine Once-Daily, Preservative-Free, Ophthalmic Formulation. <i>Advances in Therapy</i> , 2021, 38, 4070-4081.	1.3	1
28	Genetic Polymorphisms Associated With the Pharmacokinetics, Pharmacodynamics and Adverse Effects of Olanzapine, Aripiprazole and Risperidone. <i>Frontiers in Pharmacology</i> , 2021, 12, 711940.	1.6	24
29	Growth arrest and DNA damage-inducible proteins (GADD45) in psoriasis. <i>Scientific Reports</i> , 2021, 11, 14579.	1.6	11
30	PriME-PGx: La Princesa University Hospital Multidisciplinary Initiative for the Implementation of Pharmacogenetics. <i>Journal of Clinical Medicine</i> , 2021, 10, 3772.	1.0	12
31	Variants in COMT, CYP3A5, CYP2B6, and ABCG2 Alter Quetiapine Pharmacokinetics. <i>Pharmaceutics</i> , 2021, 13, 1573.	2.0	4
32	The pharmacogenetics of treatment with olanzapine. <i>Pharmacogenomics</i> , 2021, 22, 939-958.	0.6	11
33	ABCB1 C3435T, G2677T/A and C1236T variants have no effect in eslicarbazepine pharmacokinetics. <i>Biomedicine and Pharmacotherapy</i> , 2021, 142, 112083.	2.5	3
34	The safety of drugs for inflammatory bowel disease during pregnancy and breastfeeding: the DUMBO registry study protocol of GETECCU. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 17562848211018097.	1.4	11
35	HCP5 rs2395029 is a rapid and inexpensive alternative to HLA-B*57:01 genotyping to predict abacavir hypersensitivity reaction in Spain. <i>Pharmacogenetics and Genomics</i> , 2021, 31, 53-59.	0.7	4
36	Effects of Cytochrome P450 and Transporter Polymorphisms on the Bioavailability and Safety of Dutasteride and Tamsulosin. <i>Frontiers in Pharmacology</i> , 2021, 12, 718281.	1.6	4

#	ARTICLE	IF	CITATIONS
37	Clinical Relevance of Novel Polymorphisms in the Dihydropyrimidine Dehydrogenase (DPYD) Gene in Patients with Severe Fluoropyrimidine Toxicity: A Spanish Case-Control Study. <i>Pharmaceutics</i> , 2021, 13, 2036.	2.0	8
38	Influence of CYP2B6 activity score on the pharmacokinetics and safety of single dose efavirenz in healthy volunteers. <i>Pharmacogenomics Journal</i> , 2020, 20, 235-245.	0.9	10
39	Effective quantification of 11 tyrosine kinase inhibitors and caffeine in human plasma by validated LC-MS/MS method with potent phospholipids clean-up procedure. Application to therapeutic drug monitoring. <i>Talanta</i> , 2020, 208, 120450.	2.9	43
40	Physiologically Based Pharmacokinetic Modelling to Describe the Pharmacokinetics of Risperidone and 9-Hydroxyrisperidone According to Cytochrome P450 2D6 Phenotypes. <i>Clinical Pharmacokinetics</i> , 2020, 59, 51-65.	1.6	15
41	Effects of aripiprazole on circadian prolactin secretion related to pharmacogenetics in healthy volunteers. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2020, 126, 236-246.	1.2	7
42	Author's Response to: "Letter to the Editor in Response to: "Effect of Polymorphisms in CYP2C9 and CYP2C19 on the Disposition, Safety and Metabolism of Progesterone Administered Orally or Vaginally". <i>Advances in Therapy</i> , 2020, 37, 965-967.	1.3	0
43	Genome-wide association analysis of psoriasis patients treated with anti-TNF drugs. <i>Experimental Dermatology</i> , 2020, 29, 1225-1232.	1.4	11
44	Polymorphisms associated with optimization of biological therapy through drug dose reduction in moderate-to-severe psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e271-e275.	1.3	7
45	Effect of food on the pharmacokinetics of omeprazole, pantoprazole and rabeprazole. <i>BMC Pharmacology &amp; Toxicology</i> , 2020, 21, 54.	1.0	19
46	Important Pharmacogenetic Information for Drugs Prescribed During the SARS-CoV-2 Infection (COVID-19). <i>Clinical and Translational Science</i> , 2020, 13, 1023-1033.	1.5	11
47	Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial. <i>Trials</i> , 2020, 21, 772.	0.7	15
48	Pharmacogenetics Update on Biologic Therapy in Psoriasis. <i>Medicina (Lithuania)</i> , 2020, 56, 719.	0.8	11
49	Effect of Cytochrome P450 and ABCB1 Polymorphisms on Imatinib Pharmacokinetics After Single-Dose Administration to Healthy Subjects. <i>Clinical Drug Investigation</i> , 2020, 40, 617-628.	1.1	10
50	The pharmacogenetics of aripiprazole-induced hyperprolactinemia: what do we know?. <i>Pharmacogenomics</i> , 2020, 21, 571-574.	0.6	6
51	Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study. <i>Lancet</i> , 2020, 395, 1705-1714.	6.3	347
52	Involvement of CYP2D6 and CYP2B6 on tramadol pharmacokinetics. <i>Pharmacogenomics</i> , 2020, 21, 663-675.	0.6	8
53	Urgent Hospital Admissions Caused by Adverse Drug Reactions and Medication Errors: A Population-Based Study in Spain. <i>Frontiers in Pharmacology</i> , 2020, 11, 734.	1.6	12
54	Effect of Sex, Use of Pantoprazole and Polymorphisms in SLC22A1, ABCB1, CES1, CYP3A5 and CYP2D6 on the Pharmacokinetics and Safety of Dabigatran. <i>Advances in Therapy</i> , 2020, 37, 3537-3550.	1.3	16

#	ARTICLE	IF	CITATIONS
55	The effects of aripiprazole and olanzapine on pupillary light reflex and its relationship with pharmacogenetics in a randomized multiple-dose trial. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 2051-2062.	1.1	19
56	Effect of the Most Relevant CYP3A4 and CYP3A5 Polymorphisms on the Pharmacokinetic Parameters of 10 CYP3A Substrates. <i>Biomedicines</i> , 2020, 8, 94.	1.4	57
57	The effect of CYP2D6 variation on antipsychotic-induced hyperprolactinaemia: a systematic review and meta-analysis. <i>Pharmacogenomics Journal</i> , 2020, 20, 629-637.	0.9	10
58	Fendrix vs Engerix-B for Primo-Vaccination Against Hepatitis B Infection in Patients With Inflammatory Bowel Disease: A Randomized Clinical Trial. <i>American Journal of Gastroenterology</i> , 2020, 115, 1802-1811.	0.2	12
59	Randomised multicentre clinical trial to evaluate voriconazole pre-emptive genotyping strategy in patients with risk of aspergillosis: vorigenipharm study protocol. <i>BMJ Open</i> , 2020, 10, e037443.	0.8	2
60	Prediction models for voriconazole pharmacokinetics based on pharmacogenetics: AN exploratory study in a Spanish population. <i>International Journal of Antimicrobial Agents</i> , 2019, 54, 463-470.	1.1	17
61	Effect of Polymorphisms in CYP2C9 and CYP2C19 on the Disposition, Safety and Metabolism of Progesterone Administrated Orally or Vaginally. <i>Advances in Therapy</i> , 2019, 36, 2744-2755.	1.3	6
62	A Neutrophil Timer Coordinates Immune Defense and Vascular Protection. <i>Immunity</i> , 2019, 50, 390-402.e10.	6.6	258
63	Influence of CYP450 Enzymes, CES1, PON1, ABCB1, and P2RY12 Polymorphisms on Clopidogrel Response in Patients Subjected to a Percutaneous Neurointervention. <i>Clinical Therapeutics</i> , 2019, 41, 1199-1212.e2.	1.1	23
64	Investigation on the Existence of Sex-by-Formulation Interaction in Bioequivalence Trials. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 1099-1112.	2.3	4
65	Sex-by-formulation interaction in bioequivalence trials with transdermal patches. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 801-808.	0.8	1
66	Simultaneous determination of six antipsychotics, two of their metabolites and caffeine in human plasma by LC-MS/MS using a phospholipid-removal microelution-solid phase extraction method for sample preparation. <i>Talanta</i> , 2019, 198, 159-168.	2.9	39
67	Response to "Sex-by-formulation interaction in bioequivalence studies: the importance of formulations and experimental conditions"™ by Ibarra et al.. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 857-858.	1.1	1
68	Polymorphisms in <i>CYP1A2</i> , <i>CYP2C9</i> and <i>ABCB1</i> affect agomelatine pharmacokinetics. <i>Journal of Psychopharmacology</i> , 2019, 33, 522-531.	2.0	36
69	Utility of Therapeutic Drug Monitoring of Imatinib, Nilotinib, and Dasatinib in Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis. <i>Clinical Therapeutics</i> , 2019, 41, 2558-2570.e7.	1.1	31
70	Modificaciones y exenciones del consentimiento informado y las guías Council for International Organizations of Medical Sciences. <i>Medicina Clínica</i> , 2019, 152, 78-79.	0.3	0
71	<i>CYP2C19</i> Ultrarapid Phenotype as a Risk Predictor of Subsequent Events During Clopidogrel Treatment in Patients Undergoing a Percutaneous Neurointervention. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 1074-1075.	2.3	1
72	Polymorphisms associated with anti-TNF drugs response in patients with psoriasis and psoriatic arthritis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, e175-e177.	1.3	13

#	ARTICLE	IF	CITATIONS
73	Influence of thiopurine Sâ€methyltransferase polymorphisms in mercaptopurine pharmacokinetics in healthy volunteers. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2019, 124, 449-455.	1.2	8
74	Polymorphisms associated with fentanyl pharmacokinetics, pharmacodynamics and adverse effects. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2019, 124, 321-329.	1.2	39
75	Influence of <i>CYP2C19</i> Phenotype on the Effect of Clopidogrel in Patients Undergoing a Percutaneous Neurointervention Procedure. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 661-671.	2.3	16
76	Evaluation of sexâ€byâ€formulation interaction in bioequivalence studies of efavirenz tablets. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 1729-1737.	1.1	6
77	Effective phospholipids removing microelution-solid phase extraction LC-MS/MS method for simultaneous plasma quantification of aripiprazole and dehydro-aripiprazole: Application to human pharmacokinetic studies. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018, 151, 116-125.	1.4	22
78	Influence of <i>CYP2D6</i> , <i>CYP3A4</i> , <i>CYP3A5</i> and <i>ABCB1</i> Polymorphisms on Pharmacokinetics and Safety of Aripiprazole in Healthy Volunteers. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2018, 122, 596-605.	1.2	55
79	Effect of ABCB1 C3435T Polymorphism on Pharmacokinetics of Antipsychotics and Antidepressants. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2018, 123, 474-485.	1.2	51
80	New polymorphisms associated with response to anti-TNF drugs in patients with moderate-to-severe plaque psoriasis. <i>Pharmacogenomics Journal</i> , 2018, 18, 70-75.	0.9	31
81	IL17RA gene variants and anti-TNF response among psoriasis patients. <i>Pharmacogenomics Journal</i> , 2018, 18, 76-80.	0.9	28
82	Epigenetic biomarkers associated with antitumour necrosis factor drug response in moderate-to-severe psoriasis. <i>British Journal of Dermatology</i> , 2018, 178, 798-800.	1.4	13
83	Pharmacogenetics and Pharmacogenomics in Moderate-to-Severe Psoriasis. <i>American Journal of Clinical Dermatology</i> , 2018, 19, 209-222.	3.3	39
84	Polymorphisms associated with adalimumab and infliximab response in moderate-to-severe plaque psoriasis. <i>Pharmacogenomics</i> , 2018, 19, 7-16.	0.6	21
85	Effect of Polymorphisms on the Pharmacokinetics, Pharmacodynamics and Safety of Sertraline in Healthy Volunteers. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2018, 122, 501-511.	1.2	45
86	Effects of aripiprazole on pupillometric parameters related to pharmacokinetics and pharmacogenetics after single oral administration to healthy subjects. <i>Journal of Psychopharmacology</i> , 2018, 32, 1212-1222.	2.0	10
87	Histone modifications associated with biological drug response in moderateâ€toâ€severe psoriasis. <i>Experimental Dermatology</i> , 2018, 27, 1361-1371.	1.4	48
88	How to make P-glycoprotein ( <i>ABCB1</i> , <i>MDR1</i> ) harbor mutations and measure its expression and activity in cell cultures?. <i>Pharmacogenomics</i> , 2018, 19, 1285-1297.	0.6	7
89	Appropriateness of the use of proton pump inhibitors in the Emergency Department of a Spanish university hospital. <i>Revista Espanola De Enfermedades Digestivas</i> , 2018, 111, 755-761.	0.1	2
90	Strategies to design clinical studies to identify predictive biomarkers in cancer research. <i>Cancer Treatment Reviews</i> , 2017, 53, 79-97.	3.4	80

#	ARTICLE	IF	CITATIONS
91	Polymorphisms associated with etanercept response in moderate-to-severe plaque psoriasis. <i>Pharmacogenomics</i> , 2017, 18, 631-638.	0.6	25
92	Simultaneous Determination of Imatinib, Dasatinib, and Nilotinib by Liquid Chromatography-Tandem Mass Spectrometry and Its Application to Therapeutic Drug Monitoring. <i>Therapeutic Drug Monitoring</i> , 2017, 39, 252-262.	1.0	16
93	Pharmacogenetics of ustekinumab in patients with moderate-to-severe plaque psoriasis. <i>Pharmacogenomics</i> , 2017, 18, 157-164.	0.6	24
94	Pharmacogenetics of trazodone in healthy volunteers: association with pharmacokinetics, pharmacodynamics and safety. <i>Pharmacogenomics</i> , 2017, 18, 1491-1502.	0.6	11
95	Pharmacogenetics of methylphenidate in childhood attention-deficit/hyperactivity disorder: long-term effects. <i>Scientific Reports</i> , 2017, 7, 10391.	1.6	18
96	Association between Genetic Polymorphisms and Response to Anti-TNFs in Patients with Inflammatory Bowel Disease. <i>International Journal of Molecular Sciences</i> , 2016, 17, 225.	1.8	26
97	Effect of Truncating $AUC$ at 12, 24 and 48Åhr When Evaluating the Bioequivalence of Drugs with a Long Half-Life. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2016, 118, 53-57.	1.2	3
98	Consumption of Drugs and Nonpharmacological Therapies in Caregivers of Patients with Alzheimer's Disease: A Case-Control Study in Madrid. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2016, 6, 68-77.	0.6	6
99	Evaluation of the Relationship Between Pharmacokinetics and the Safety of Aripiprazole and Its Cardiovascular Effects in Healthy Volunteers. <i>Journal of Clinical Psychopharmacology</i> , 2016, 36, 608-614.	0.7	15
100	Utility of Pilot Studies for Predicting Ratios and Intrasubject Variability in High-Variability Drugs. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2016, 119, 215-221.	1.2	4
101	Paradoxical psoriasiform reactions to anti-TNF± drugs are associated with genetic polymorphisms in patients with psoriasis. <i>Pharmacogenomics Journal</i> , 2016, 16, 336-340.	0.9	45
102	Electronic medical record in clinical trials of effectiveness of drugs integrated in clinical practice. <i>Medicina Clínica (English Edition)</i> , 2015, 145, 452-457.	0.1	1
103	Attention deficit hyperactivity disorder: genetic association study in a cohort of Spanish children. <i>Behavioral and Brain Functions</i> , 2015, 12, 2.	1.4	26
104	Improvement and Validation of a High-Performance Liquid Chromatography in Tandem Mass Spectrometry Method for Monitoring of Omeprazole in Plasma. <i>Therapeutic Drug Monitoring</i> , 2015, 37, 381-388.	1.0	3
105	Polymorphisms Associated with Age at Onset in Patients with Moderate-to-Severe Plaque Psoriasis. <i>Journal of Immunology Research</i> , 2015, 2015, 1-8.	0.9	17
106	New immune system genetic polymorphisms associated with moderate-to-severe plaque psoriasis: a case-control study. <i>British Journal of Dermatology</i> , 2015, 172, 1432-1435.	1.4	8
107	Pharmacogenetics of quetiapine in healthy volunteers. <i>International Clinical Psychopharmacology</i> , 2015, 30, 82-88.	0.9	23
108	The polymorphism rs763780 in the <i>IL-17F</i> gene is associated with response to biological drugs in patients with psoriasis. <i>Pharmacogenomics</i> , 2015, 16, 1723-1731.	0.6	45

#	ARTICLE	IF	CITATIONS
109	Effect of gender and <i>CYP2C9</i> and <i>CYP2C8</i> polymorphisms on the pharmacokinetics of ibuprofen enantiomers. <i>Pharmacogenomics</i> , 2015, 16, 939-948.	0.6	25
110	Polymorphisms in <i>CYP2D6</i> have a Greater Effect on Variability of Risperidone Pharmacokinetics than Gender. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2015, 116, 124-128.	1.2	17
111	Evaluation of the relationship between polymorphisms in <i>CYP2C19</i> and the pharmacokinetics of omeprazole, pantoprazole and rabeprazole. <i>Pharmacogenomics</i> , 2014, 15, 1893-1901.	0.6	23
112	Effect of polymorphisms on the pharmacokinetics, pharmacodynamics, and safety of risperidone in healthy volunteers. <i>Human Psychopharmacology</i> , 2014, 29, 459-469.	0.7	33
113	Tu1938 Identification of New Genetic Variants Related to Thiopurine-Induced Myelotoxicity in Inflammatory Bowel Disease (IBD) Patients With Normal Thiopurines-Methyltransferase (TPMT): A Genome-Wide Association Study. <i>Gastroenterology</i> , 2014, 146, S-877.	0.6	0
114	Tu1704 Effect of Chondroitin Sulphate on Pro-Inflammatory Mediators and Disease Activity in Patients With Inflammatory Bowel Disease (IBD). <i>Gastroenterology</i> , 2014, 146, S-822.	0.6	0
115	Use of pharmacogenetics in bioequivalence studies to reduce sample size: an example with mirtazapine and CYP2D6. <i>Pharmacogenomics Journal</i> , 2013, 13, 452-455.	0.9	12
116	Pharmacodynamic genetic variants related to antipsychotic adverse reactions in healthy volunteers. <i>Pharmacogenomics</i> , 2013, 14, 1203-1214.	0.6	9
117	Su1752 Identification of New Genetic Variants Related to Thiopurine-Induced Myelotoxicity in Inflammatory Bowel Disease (IBD) Patients With Normal Thiopurines-Methyltransferase (TPMT): A Genome-Wide Association Study. <i>Gastroenterology</i> , 2013, 144, S-467.	0.6	1
118	A simple assay for the simultaneous determination of human plasma alendazole and alendazole sulfoxide levels by high performance liquid chromatography in tandem mass spectrometry with solid-phase extraction. <i>Clinica Chimica Acta</i> , 2013, 426, 58-63.	0.5	20
119	Gene polymorphisms that can predict response to anti-TNF therapy in patients with psoriasis and related autoimmune diseases. <i>Pharmacogenomics Journal</i> , 2013, 13, 297-305.	0.9	66
120	Polymorphisms influencing olanzapine metabolism and adverse effects in healthy subjects. <i>Human Psychopharmacology</i> , 2013, 28, 205-214.	0.7	43
121	CYP2D6 poor metabolizer status might be associated with better response to risperidone treatment. <i>Pharmacogenetics and Genomics</i> , 2013, 23, 627-630.	0.7	25
122	Genetics of Psoriasis and Pharmacogenetics of Biological Drugs. <i>Autoimmune Diseases</i> , 2013, 2013, 1-13.	2.7	55
123	Evaluation of the relationship between polymorphisms in <i>CYP2C8</i> and <i>CYP2C9</i> and the pharmacokinetics of celecoxib. <i>Journal of Clinical Pharmacology</i> , 2013, 53, 1261-1267.	1.0	28
124	Evaluation of the Relationship between Sex, Polymorphisms in <i>CYP2C8</i> and <i>CYP2C9</i> , and Pharmacokinetics of Angiotensin Receptor Blockers. <i>Drug Metabolism and Disposition</i> , 2013, 41, 224-229.	1.7	45
125	Pharmacogenetics of topical and systemic treatment of psoriasis. <i>Pharmacogenomics</i> , 2013, 14, 1623-1634.	0.6	29
126	The relationship between tumour necrosis factor (TNF)- $\beta$ promoter and <i>IL12B</i> / <i>IL-23R</i> genes polymorphisms and the efficacy of anti-TNF- $\beta$ therapy in psoriasis: a case-control study. <i>British Journal of Dermatology</i> , 2013, 169, 819-829.	1.4	66



#	ARTICLE	IF	CITATIONS
127	Association of common genetic variants with risperidone adverse events in a Spanish schizophrenic population. <i>Pharmacogenomics Journal</i> , 2013, 13, 197-204.	0.9	20
128	Association between psoriasis and polymorphisms in the TNF, IL12B, and IL23R genes in Spanish patients. <i>European Journal of Dermatology</i> , 2013, 23, 640-645.	0.3	19
129	Utility of Assessing Thiopurine S-methyltransferase Polymorphisms Before Azathioprine Therapy. <i>Current Drug Metabolism</i> , 2012, 13, 1277-1293.	0.7	9
130	Efficiency and effectiveness of the use of an acenocoumarol pharmacogenetic dosing algorithm versus usual care in patients with venous thromboembolic disease initiating oral anticoagulation: study protocol for a randomized controlled trial. <i>Trials</i> , 2012, 13, 239.	0.7	15
131	Toward a clinical practice guide in pharmacogenomics testing for functional polymorphisms of drug-metabolizing enzymes. Gene/drug pairs and barriers perceived in Spain. <i>Frontiers in Genetics</i> , 2012, 3, 273.	1.1	23
132	Validation of a Genotyping Method for Analysis of TPMT Polymorphisms. <i>Clinical Therapeutics</i> , 2012, 34, 878-884.	1.1	9
133	Genetic Variants of Interferon-Stimulated Genes and IL-28B as Host Prognostic Factors of Response to Combination Treatment for Chronic Hepatitis C. <i>Clinical Pharmacology and Therapeutics</i> , 2011, 90, 712-721.	2.3	18
134	DRD2 Taq1A Polymorphism Modulates Prolactin Secretion Induced by Atypical Antipsychotics in Healthy Volunteers. <i>Journal of Clinical Psychopharmacology</i> , 2011, 31, 555-562.	0.7	32
135	ATA homozygosity in the IL-10 gene promoter is a risk factor for schizophrenia in Spanish females: a case control study. <i>BMC Medical Genetics</i> , 2011, 12, 81.	2.1	15
136	Effects of CYP2D6 Genotype on the Pharmacokinetics, Pharmacodynamics, and Safety of Risperidone in Healthy Volunteers. <i>Journal of Clinical Psychopharmacology</i> , 2010, 30, 504-511.	0.7	57
137	Use of non-specific intravenous human immunoglobulins in Spanish hospitals; need for a hospital protocol. <i>European Journal of Clinical Pharmacology</i> , 2010, 66, 633-641.	0.8	18
138	Evaluating a newly developed pharmacogenetic array: screening in a Spanish population. <i>Pharmacogenomics</i> , 2010, 11, 1619-1625.	0.6	12
139	W1262 Genetic Mutations of Thiopurine-Methyltransferase (TPMT) in Inflammatory Bowel Disease Patients With Normal TPMT Phenotype and Thiopurine-Induced Myelotoxicity. <i>Gastroenterology</i> , 2010, 138, S-686.	0.6	0
140	Pharmacogenetic relevance of the CYP2C93 allele in a tenoxicam bioequivalence study performed on Spaniards. <i>Pharmacological Research</i> , 2009, 59, 62-68.	3.1	13
141	Influence of sex and CYP2D6 genotype on mirtazapine disposition, evaluated in Spanish healthy volunteers. <i>Pharmacological Research</i> , 2009, 59, 393-398.	3.1	27
142	Influence of CYP2C8 and CYP2C9 polymorphisms on pharmacokinetic and pharmacodynamic parameters of racemic and enantiomeric forms of ibuprofen in healthy volunteers. <i>Pharmacological Research</i> , 2008, 58, 77-84.	3.1	59
143	Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial. <i>Vaccine</i> , 2008, 26, 2378-2388.	1.7	86
144	Lithium and venlafaxine interaction: a case of serotonin syndrome. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2006, 31, 397-400.	0.7	37

#	ARTICLE	IF	CITATIONS
145	Comparison of Gastric Endoscopic Lesions and Tolerability to Ibuprofen and Ibuprofen-Arginate in Healthy Subjects. <i>Journal of Clinical Gastroenterology</i> , 2005, 39, 834-835.	1.1	5
146	Albumin prevents mitochondrial depolarization and apoptosis elicited by endoplasmic reticulum calcium depletion of neuroblastoma cells. <i>European Journal of Pharmacology</i> , 2005, 520, 1-11.	1.7	20
147	An eutomer/distomer ratio near unity does not justify non-enantiospecific assay methods in bioequivalence studies. <i>Chirality</i> , 2005, 17, 470-475.	1.3	18
148	Assessment of sex differences in pharmacokinetics and pharmacodynamics of amlodipine in a bioequivalence study. <i>Pharmacological Research</i> , 2005, 51, 445-452.	3.1	44
149	The comparative hemodynamic effects of intravenous IQB-9302 and bupivacaine in anesthetized rats. <i>Acta Anaesthesiologica Scandinavica</i> , 2004, 48, 607-612.	0.7	0
150	Effect of Ibuprofen on Cyclooxygenase and Nitric Oxide Synthase of Gastric Mucosa: Correlation with Endoscopic Lesions and Adverse Reactions. <i>Digestive Diseases and Sciences</i> , 2004, 49, 1538-1544.	1.1	10
151	Gender Differences in Angiotensin-Converting Enzyme (ACE) Activity and Inhibition by Enalaprilat in Healthy Volunteers. <i>Journal of Cardiovascular Pharmacology</i> , 2004, 43, 737-744.	0.8	51
152	Pharmacokinetics and Pharmacodynamics of a Single Bolus of Propofol 2% in Healthy Volunteers. <i>Journal of Clinical Pharmacology</i> , 2003, 43, 397-405.	1.0	13
153	Survey of oral hydrocortisone utilization in Madrid (Spain). <i>Pharmacological Research</i> , 2002, 45, 15-20.	3.1	1
154	Ulnar Nerve Block Induced by the New Local Anesthetic IQB-9302 in Healthy Volunteers: A Comparison with Bupivacaine. <i>Anesthesia and Analgesia</i> , 2001, 93, 1316-1320.	1.1	3
155	Do Muscarinic Receptors Play a Role in Acute Pancreatitis?. <i>Clinical Drug Investigation</i> , 2000, 20, 401-408.	1.1	2
156	Digoxin Level and Clinical Manifestations as Determinants in the Diagnosis of Digoxin Toxicity. <i>Therapeutic Drug Monitoring</i> , 2000, 22, 163-168.	1.0	29
157	Novel antimigraineur dotarizine releases Ca <sup>2+</sup> from caffeine-sensitive Ca <sup>2+</sup> stores of chromaffin cells. <i>British Journal of Pharmacology</i> , 1999, 128, 621-626.	2.7	6
158	Effects of dotarizine and flunarizine on chromaffin cell viability and cytosolic Ca <sup>2+</sup> . <i>European Journal of Pharmacology</i> , 1999, 366, 309-317.	1.7	22
159	Evaluation of Sex Differences in the Pharmacokinetics of Ranitidine in Humans. <i>Journal of Clinical Pharmacology</i> , 1996, 36, 748-751.	1.0	10
160	Nimodipine Transfer into Human Breast Milk and Cerebrospinal Fluid. <i>Annals of Pharmacotherapy</i> , 1996, 30, 148-150.	0.9	12